Biodexa Pharmaceuticals PLC ADR美国存托凭证招股说明书（2025年6月2日版）

BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in ourRegistration Statement on Form F-1, as amended, effective as of May 9, 2025 (the “Prospectus”), related to the resale by the sellingshareholders identified in the Prospectus of up to an aggregate of 4,349,102,800 of our ordinary shares, nominal value £0.00005 per This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the informationcontained in our attached Form 6-K, filed with the Securities and Exchange Commission on May 30, 2025. This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectusexcept to the extent that the information in this Prospectus Supplement supersedes the information contained therein. Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing priceof Depositary Shares on the NASDAQ Capital Market on May 30, 2025 was $1.08. Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of the Prospectus and in thedocuments incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal The date of this Prospectus Supplement is June 2, 2025. FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIESEXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number:001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom(Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-FxForm 40-F¨ The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall itbe deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exhibit Number Press release dated May 30, 2025 99.1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on itsbehalf by the undersigned, thereunto duly authorized. Shareholder Update Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical companydeveloping a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update Financial position As of May 29, 2025, the Company had access to the following cash resources: Cash at bank Cash in escrow for eRapa Phase 3 program Undrawn CPRIT grant for eRapa Phase 3 program Debt The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based on its latestprojections, the Company has sufficient working capital to fund operations into the first quarter of 2026. Issued shares, total voting rights, market capitalization As of May 29, 2025, there were 50,506,308,922 ordinary shares, equivalent to 5,050,630 American Depositary Shares (ADSs),outstanding. The Company holds zero shares in treasury and therefore the number of voting rights is the same as the number of Based on the closing share price on May 29, 2025 of $1.06 per ADS, the Company’s market capitalization was $5.4 million. eRapa Phase 3 program The Phase 3 study of eRapa in FAP is in the final stages of implementation. It will be a double-blind placebo-controlled trial in 168patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US andEurope. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European componentwill be conducted by Precision for Medicine LLC. All planned US sites and the majority of European sites have been identified. About FAP FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approvedtherapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain thestandard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported prevalence of